-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on LB Pharmaceuticals, Raises Price Target to $40

Benzinga·03/27/2026 13:47:18
Listen to the news
Stifel analyst Paul Matteis maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and raises the price target from $35 to $40.